Receives FDA Clearance

Related by string. * receives . RECEIVES . receive . RECEIVE : RECEIVE AN E MAIL . Iron Consulting receives . Parents Receive Graphic . Receive mediabistro.com s / fda . FDAs . Fda : Drug Administration FDA . reformulates existing FDA . FDA Orphan Drug . FDA Clearance / Clearances . CLEARANCE . clearances . clearance : slum clearance . calculated creatinine clearance . antitrust clearance * *

Related by context. All words. (Click for frequent words.) 90 Announces FDA Clearance 89 FDA Clears 85 Gets FDA Clearance 85 Completes Enrollment 83 Receives Orphan Drug Designation 82 FDA Approves 81 Completes Patient Enrollment 81 Files IND 81 FDA Clearance 80 Announce License Agreement 80 Sign Licensing Agreement 80 Enrolls First 80 FDA Approvals 80 Submits NDA 79 Introduces Revolutionary 79 Receives Approvable Letter 79 Initiates Clinical Trial 79 Initiates Phase II 79 Awarded Patent 79 Receives Patent 79 Files Patent Application 78 k Clearance 78 Obtains FDA 78 Presents Positive 78 Introduces Next Generation 78 Sign License Agreement 78 Initiates Enrollment 78 Patent Issued 78 Announces Initiation 77 Receives CE 77 Demonstrates Significant 77 FDA Okays 77 ORLive Presents 76 Drug Candidate 76 Shows Promise 76 Develop Novel 76 Submits Application 76 FDA Accepts 76 IND Application 76 Signs Licensing Agreement 76 Presents Preclinical Data 76 Clinical Trial Results 76 Licenses Novel 76 Receives Milestone Payment 76 Begins Shipment 76 Commercializes 76 FDA Approval 76 Files Patent 75 Begins Shipping 75 Initiates Clinical 75 Improves Survival 75 Achieves Milestone 75 Non Invasive 75 Receives SFDA Approval 75 Clinical Trial Evaluating 75 Initiates Clinical Trials 75 Patient Enrollment 75 Significantly Reduces 75 Reduces Risk 75 Announces Immediate Availability 75 Announce Availability 75 Announce Collaboration Agreement 75 Announce Collaboration 75 Commences Phase 75 Launches Next Generation 75 Announce Licensing Agreement 75 Announces Tentative Approval 75 Announce Merger Agreement 75 Receives Clearance 75 Molecular Diagnostic Test 75 Announces Licensing Agreement 75 Receives Approval 75 Improves Outcomes 74 Present Preclinical Data 74 Introduces Novel 74 Shows Promising 74 Meets Primary Endpoint 74 Patients Undergoing 74 Significantly Improves 74 PRN FDA Approves 74 Study Evaluating 74 Announces License Agreement 74 Submits Biologics License Application 74 Develop Next Generation 74 Releases Next Generation 74 Announces Positive 74 Introduces Innovative 74 Announces Publication 74 Study Demonstrates 74 Patients Treated With 74 Expand Collaboration 74 Therapeutic Competitors Companies 74 Introduces Breakthrough 74 Taro Receives 73 Granted Orphan Drug 73 Obtains Approval 73 Submits IND 73 Expanded Indication 73 Begins Dosing 73 Phase III Clinical Trial 73 AnaSpec Introduces 73 Reports Positive 73 Demonstrates Positive 73 Receives CE Marking 73 Phase III Trial 73 Mylan Receives Approval 73 Effectively Treats 73 Introduces Enhanced 73 Awarded Patents 73 Enters Agreement 73 Receives Tentative Approval 73 Achieves Primary Endpoint 73 Drug Fails 73 Pivotal Study 73 Cypher Sirolimus 73 Vascular Grafts 73 Less Invasive 73 Patent Covering 73 Obtains License 73 Reveals Positive 73 FDA Warns 73 Phase 2b Clinical Trial 73 Strengthens Position 72 Receives Orphan Drug 72 Submits Supplemental 72 Single Dose 72 Novel Oral 72 Initiates Phase III 72 Announces Availability 72 Clinical Study Shows 72 NDA Submission 72 Announces Successful Completion 72 Receives Regulatory 72 Successfully Tests 72 Announces Presentation 72 Preclinical Data 72 Eliminates Need 72 Signs License Agreement 72 Settle Patent Litigation 72 Collaborators Present 72 Initiates Phase 72 Test Detects 72 Receives Positive 72 Successfully Treated 72 Drug Shows Promise 72 Initiate Clinical Trial 72 Develops Innovative 72 Successfully Treats 72 Commercially Available 72 Delivers Next Generation 72 Nasdaq SMTS develops manufactures 72 Generic Versions 72 Announce Agreement 72 First Patient Treated 72 Receives Positive Opinion 72 Significantly Increases 72 Generic Version 72 Dry Powder Inhaler 72 Submits Response 72 Launches Generic Version 72 Unveils Next Generation 72 Successfully Completed 72 Successfully Tested 72 Unveils Innovative 72 Demonstrates Potential 72 Tumor Targeting 72 Unveils Revolutionary 72 Acquires Exclusive 72 Proves Successful 72 Holds Promise 72 Initiates Dosing 72 REMINDER ORLive Presents 72 Phase IIb Trial 72 Provides Update Regarding 72 Transdermal Patch 72 Proven Effective 71 Launches Innovative 71 Vitrasert R 71 Adjuvant Treatment 71 Unveils Latest 71 Drug Eluting Coronary Stent 71 Prolongs Survival 71 Commercialize 71 Obtains CE Mark 71 Completes Installation 71 Investigational Compound 71 Receives Favorable 71 Phase IIb Clinical Trial 71 Expands Capabilities 71 Patients Treated 71 Absorbable 71 Reports Preclinical Data 71 Finalizes Acquisition 71 Completes Successful 71 Improves Quality 71 Investigational Oral 71 Introduces Unique 71 Shows Promise Against 71 Successfully Completes 71 Novartis Novo Nordisk 71 Pivotal Trial 71 Announces Issuance 71 Contrast Enhanced 71 Pharmaceuticals Initiates 71 Obtains Exclusive License 71 Receives Order 71 Commence Phase 71 Inks Licensing Deal 71 Phase IIa Clinical Trial 71 Reduces Pain 71 Drug Eluting 71 Presents Positive Preclinical 71 Announces Enhancements 71 Strengthens Its 71 Amends Agreement 71 BioSante Pharmaceuticals Announces 71 Phase 2b Trial 71 Successfully Completes Phase 71 Treatment Reduces 71 Launches Enhanced 71 Discontinues 71 Cerebral Somatic Oximeter 71 Receives Fast Track 71 Non Invasive Treatment 70 Expands Portfolio 70 Arthritis Drug 70 Proves Effective 70 Presents Preclinical 70 Settle Patent Dispute 70 Provides Guidance 70 FDA Panel Recommends 70 Awarded Qualifying Therapeutic 70 Contrast Agent 70 Achieves Certification 70 Improves Efficiency 70 Protects Against 70 Patients Enrolled 70 Osteoporosis Drug 70 Acquire Assets 70 Investigational Treatment 70 Cholesterol Lowering Drug 70 Milestone Payment 70 Balloon Catheter 70 Bullish Engulfing Pattern 70 Receives Notification 70 Increases Risk 70 Flagship Product 70 Successfully Completes Tender Offer 70 Complicated Skin 70 Regains Compliance With 70 Voluntarily Withdraws 70 Pivotal Phase III 70 Teva Provides Update 70 Receives Notice 70 Nasopharyngeal Electrodes Needle Electrodes 70 Rheumatoid Arthritis Drug 70 Enters Into Agreement 70 Launches Unique 70 Blood Thinner 70 Provide Comprehensive 70 Regains Compliance 70 Jointly Develop 70 Issued Patent 70 Equipment Deals 70 Recall Issued 70 Settles Patent Dispute 70 Veeco Introduces 70 Pulmonary Valve 70 Announces Poster Presentations 70 Completes Merger With 70 Obtains Patent 70 Ships #th 70 Expands Functionality 70 Heart Failure Patients 70 Files Investigational 70 Agilent Technologies Introduces 70 Contrast Agents 70 Revolutionizes 70 R famotidine 70 Diagnostic Tests 70 Receives Certification 70 Embolic Protection 70 Announce Definitive Agreement 70 Successfully Deploys 70 Initiates Voluntary Recall 70 Confirms Efficacy 70 Initiate Phase III 70 Microwave Ablation System 70 Signs Agreements 69 Kinase Inhibitor 69 Trial Evaluating 69 Fully Automated 69 Wins Patent Infringement 69 Completes Tender Offer 69 Sirolimus Eluting Stent 69 ODT metoclopramide HCl PEPCID 69 Showcases Innovative 69 Introduces 69 CybeRelease Decliners 69 & Sullivan Recognizes 69 Prostate Cancer Vaccine 69 Gout Drug 69 SABER ™ 69 Balloon Catheters 69 Study Shows Benefits 69 Dramatically Increases 69 FDA APPROVES 69 Long Term Efficacy 69 Patient Treated 69 Gets Approval 69 TM Drug Eluting 69 Combination REOLYSIN R 69 Helps Prevent 69 Migraine Drug 69 Announces Definitive Agreement 69 Earns Milestone Payment 69 Drug Eluting Stent 69 Low Dose 69 Advanced Melanoma 69 Extends Collaboration 69 Combination Treatment 69 HER2 Positive 69 REPRONEX R menotropins 69 Delivers Breakthrough 69 Secures Patent 69 Osteoporosis Treatment 69 Receives NASDAQ 69 Appears Safe 69 Helps Identify 69 Phase 2a Trial 69 Psoriasis Drug 69 Completes Merger 69 Jointly Announce 69 Acquires Assets 69 Scientists Develop 69 Announces Favorable 69 Blood Pressure Drug 69 INDUSTRY ASSESSMENTS 69 High Growth Forecasted 69 Q2 Loss Narrows 69 refractory recurrent 69 Introduces Powerful 69 Laboratory pH Electrodes 69 Vascular Graft 69 Bioresorbable 69 Carotid Stent 69 Lupus Drug 69 Minimally Invasive Procedure 69 Gliadel R 69 Unveils Groundbreaking 69 Announce Initiation 69 Develops Novel 69 Completes Dosing 69 Hematology Molecular Pathology 69 injectable bulking agent 69 Study Confirms 69 Announces Commencement 69 Obtains Exclusive Rights 69 INTELLITEMP ® 69 Reports Receipt 69 Taglich Brothers Initiates Coverage 69 Exercises Option 69 IND Filing 69 Announce Receipt 69 Cardiovascular Prosthetic Devices 69 Could Detect 69 Announces Launch 69 Initiates Phase 2b 69 Breast Biopsy 69 Q3 Loss Widens 69 Injectable Gel 69 Study Showed 69 Completes Divestiture 69 Announces Termination 69 Expands Availability 69 Pivotal Clinical Trial 69 Lowers Risk 69 Secures Financing 69 includes Dideco CarboMedics 69 Previously Treated 69 Successfully Demonstrates 69 MicroMacro TM Multi 69 Regenerative Cells 69 CORTOSS R 69 Topical Treatment 68 Could Revolutionize 68 Receives Favorable Ruling 68 Spectrum Pharmaceuticals Announces 68 Dose Ranging Study 68 Board Authorizes 68 Breast Cancer Recurrence 68 Secures Contract 68 Develop Innovative 68 Named Exclusive Distributor 68 Tissue Engineered 68 Tyrosine Kinase Inhibitor 68 Expands Capacity 68 Adjunctive Therapy 68 Extends Tender Offer 68 markets COLAZAL 68 Well Tolerated 68 Intros 68 Anti Tumor Activity 68 Settles Patent Litigation 68 Acquire Privately Held 68 Shows Statistically Significant 68 Lung Cancer Drug 68 Announces Dismissal 68 Files Shelf Registration Statement 68 Options Activity 68 TM Aganocide 68 Secures Funding 68 MarketsandMarkets Global 68 Provides Comprehensive 68 PROMUS TM 68 Can Detect 68 Spinal Fusion 68 Mutually Agree 68 Platform Enables 68 Help Detect 68 Pipette Tips Racks Tanks 68 PerkinElmer Introduces 68 Verisyse TM intraocular lenses 68 Establish Joint Venture 68 Transdermal Drug 68 Settles Litigation 68 Device Maker 68 DIURIL R 68 Toshiba Develops 68 Files Registration Statement 68 Files Patent Infringement 68 Therapy Reduces 68 Drug Resistant 68 Generic Version Of 68 Announces Completion 68 vapreotide acetate 68 Options Trader Alert 68 Pediatric Patients 68 endoscopic autofluorescence imaging 68 Q1 Loss Narrows 68 products visit www.#M.com/touch# 68 Boosts Productivity 68 Syneron logo 68 Clinical Evaluation 68 Antimicrobial Coating 68 Expand Relationship 68 Novel Method 68 Further Validates 68 Antitumor Activity 68 Supplemental Biologics License Application 68 Anti Inflammatory 68 Helps Predict 68 Cholesterol Drug 68 Being Studied 68 Jumps Higher 68 Prospective Randomized 68 Therapy Improves 68 Phase 2a Clinical Trial 68 Subsidiary Enters 68 benzoic acid hyoscyamine sulfate 68 Receives Conditional 68 INTELLITEMP ® Energy 68 Effective Than 68 Phase 1b Clinical Trial 68 Nicotine Vaccine 68 Unveils Newest 68 Carotid Stent System 68 Announces Stockholder Approval 68 Expands Scope 68 Controlled Study 68 Announces Intent 68 Embolic 68 Vascular Closure Device 68 Releases Enhanced 68 Ultrasound Guided 68 Sinks Lower 68 Post Operative 68 Oral Calcitonin 68 Monoclonal Antibody 68 Gene Expression Analysis 68 PATHFINDER R 68 Therapeutic Competitors Report 68 JAK2 Inhibitor 68 Signs Merger Agreement 68 Planned Acquisition 68 Provides Updates 68 Attains 68 Expands Scientific Advisory 68 Receives Complete Response 68 Mg Usa 68 Announces Voluntary Recall 68 Antiviral Drugs 68 Reacquires 68 Implantable Device 68 Results Confirm 68 Study Indicates 68 First Patient Dosed 68 & Sullivan Lauds 68 Announces Addition 68 Hypertensive Patients 68 Demonstrates Statistically Significant 68 Completes Patient Enrolment 68 Fungal Infections 68 Further Strengthens 68 Announces Successful 68 Technicals Showing Bearish 68 Technicals Showing Bullish 68 Successfully Concludes 68 Updates Status 68 Extend Collaboration 68 Collaborators Publish 68 Strengthens Leadership 68 Initiate Phase 68 Complete Merger 68 Therapeutic Antibody 68 Peripherally Inserted Central 68 Shown Effective 68 Provides Shareholder 68 Imaging Technique 68 Detection Device 68 Pooled Analysis 68 BIOLASE Announces 68 Alert Technicals Showing Bullish 68 Announces Definitive Agreements 68 Transdermal System 68 Receives Funding 68 Ablation System 68 Measurement Instruments 68 Successfully Complete 68 Circulating Tumor Cells 68 Unveils Breakthrough 68 STERIS Corporation Announces 68 Enteral Feed Devices 68 II Clinical Trial 68 Devices HealFast TM 68 Genotyping Test 68 NICE Recommends 68 External Beam 68 Thrombectomy System 68 FDA Approves Drug 68 Regains NASDAQ 68 Achieves Breakthrough 68 Announces Filing 68 Announces Expanded 68 Strengthens Balance Sheet 68 Systemic Delivery 68 Downtrend Spotted 68 Elderly Patients 68 Patents Covering 68 Treating Chronic 67 Renal Artery 67 Humanized Anti 67 Slow Progression 67 Helps Reduce 67 Accelerate Commercialization 67 Robotic Assisted 67 TM Embolic Protection 67 Starts Shipping 67 Disease Modifying 67 Slows Progression 67 platform HDL Mimetic 67 Completes Initial 67 Shows Efficacy 67 Knee Prosthesis 67 Enters Into License Agreement 67 Intraocular Lens 67 Q4 Loss Narrows 67 Severe Sepsis 67 Seasonal Influenza Vaccine 67 Completes Purchase Of 67 Voluntarily Recalls 67 Obtains FDA Clearance 67 topically applied SEPA 67 Unfractionated Heparin 67 Issues Guidance 67 Announce Strategic 67 Inhibits 67 Cell Transplants 67 Validates 67 Announces Additions 67 Therapy RecoveryRx TM 67 Inks Agreement 67 Previously Untreated 67 Guidelines Issued 67 topical gel formulation 67 COMUNICADO 67 Intravascular 67 Drug Coated Stent 67 Fibrin Sealant 67 Spinal Implant 67 Significantly Reduced 67 Q2 Loss Widens 67 Alert Technicals Showing Bearish 67 Mitral Valve Repair 67 Diabetic Foot Ulcer 67 Announces Effective Date 67 RNAi Therapeutic 67 Secures Additional 67 Restructures Operations 67 Lanthanum Carbonate 67 Orally Active 67 Announces Receipt 67 Provides Unprecedented 67 Awarded Contract 67 Prove Effective 67 Updates Guidance 67 visit www.dobimedical.com 67 Pivotal Phase 67 candidates Azedra 67 Complies With 67 Widely Used 67 lead molecular radiotherapeutic 67 Intravenous Formulation 67 Successfully Demonstrate 67 COMPLETES ACQUISITION OF 67 Achieves ISO #:# Certification [002] 67 Asthma Treatment 67 Protease Inhibitor 67 Demonstrates Ability 67 Voluntarily Withdraw 67 Solution Enables 67 Thoracic Endoprosthesis 67 Demonstrates Efficacy 67 Begin Clinical Trials 67 Medoxomil 67 Insulin Pen 67 Penetrates 67 CysDisplay R 67 Interferon Alpha 67 Completes Integration 67 ANADIGICS Announces 67 Researchers Develop 67 Immunomedics Announces 67 Significantly Improved 67 Successfully Installs 67 Q3 Loss Narrows 67 Seeks Approval 67 Patients Suffering 67 Identifies Potential 67 Dry Powder Inhalers 67 Extends Reach 67 Oral Mist 67 developing Bicifadine serotonin 67 Glucose Monitoring 67 Shareholders Approve Acquisition 67 TRANSDUR ® 67 Nasdaq XTLB 67 Epilepsy Drug 67 Mouse Model 67 Curon Control 67 Clinical Efficacy 67 R brand levalbuterol 67 Announce Settlement 67 Heart Stents 67 Commercialize Novel 67 Announces Signing 67 Announces Preliminary 67 Bullish Harami Pattern 67 Renews Agreement 67 Fortifies 67 otcstockexchange.com 67 Delivers Enhanced 67 Vaccine Adjuvant 67 Pulse Oximetry 67 Device Helps 67 endoluminal stent graft 67 Begins Clinical Trial 67 Wins Approval 67 MR Angiography 67 Introduces Affordable 67 Tecnis R 67 Repliform 67 Commences Phase III 67 Successful Completion 67 Image Guided 67 Subsidiary Receives 67 Dual Wavelength 67 BE DELAYS OMISSIONS OR 67 BY STEVE KEMME 67 Robotic Catheter System 67 Explore Strategic Alternatives 67 Enters Into Exclusive 67 Sample Preparation 67 Improves Patient 67 Stem Cell Treatment 67 candidates Azedra TM 67 pralatrexate injection folate analogue 67 Enters Into Licensing Agreement 67 Molecular Mechanism 67 Q4 Loss Widens 67 Roche LightCycler ® 67 Coronary Angiography 67 Immunoassay Systems 67 NAVISTAR R 67 Data Suggest 67 Announces Adjournment 67 Combination Therapy 67 Doubles Capacity 67 gets USFDA nod 67 Agonist MABA program 67 Improve Survival 67 Achieves Significant 67 Is Well Tolerated 67 Sirolimus Eluting 67 Closes Acquisition 67 BAG# BAG# BAG# BAG# 67 Welcomes Analyst Initiation 67 Win GoodNites ® 67 Recombinant Human 67 Inks Pact 67 Enter Into 67 Polymerase Inhibitor 67 Left Atrial Appendage 67 WRX STi +# mins 67 Forward Looking IVUS 67 3M Completes Acquisition 67 Patients Receiving 67 PROMUS R 67 CONFERENCE CALLS SOURCE 67 IS PROVIDED AS IS 67 Brain Metastases 67 Bullish Average Crossover 67 Oral Fingolimod 67 Demonstrates Improved 67 Inhaled Nitric Oxide 67 Desvenlafaxine Succinate 67 Receives Accreditation 67 Refractory Hodgkin Lymphoma 67 Adjuvant Therapy 67 Wound Dressing 67 Vaginal Gel 67 Receptor Agonist 67 Hematology Coagulation Instruments 67 Bearish Harami Pattern 67 Study Proves 67 liver resection surgeries 67 Demonstrates Interoperability 67 Recall Expanded 67 INACCURACIES IN THE DOW 66 Signs Option Agreement 66 Small Molecule 66 Anticancer Activity 66 Completes Acquisition 66 Bearish Speculation 66 Files Patents 66 Completes Reverse Merger 66 CT Angiography 66 Eluting Stent 66 Broadens Its 66 brand ciclesonide Nasal 66 Genes Involved 66 Blood Glucose Meter 66 Node Positive 66 Prostate Cancer Patients 66 Proudly Announces 66 Board Unanimously Rejects 66 Reduces Mortality 66 Avago Technologies Announces 66 Inc. Nasdaq OXGN 66 REDUCED DEMAND FOR 66 ™ Paclitaxel Eluting 66 Cholesterol Lowering 66 Bone Augmentation Material 66 Trimble Introduces 66 Hsp# Inhibitor 66 FY# Loss Widens 66 Updates Shareholders 66 Randomized Clinical Trial 66 Confirms Commitment 66 Withdraws Application 66 Licenses Patents 66 Prophylactic Treatment 66 ® VAD Ventricular 66 Anti Tumor 66 Survival Benefit 66 Cites Positive 66 Wins Contract 66 TRANSDUR ™ 66 Clinical Study 66 Regains Full 66 Paclitaxel Eluting 66 Treatment Resistant 66 Enters Into Strategic 66 Eur J 66 Significantly Enhances 66 Extends Capabilities 66 Using Dip Pen 66 Microcatheter 66 Myocardial Perfusion Imaging 66 Product Offerings 66 Endovascular Graft 66 JONES CONTENT 66 Conjugate 66 Confirms Receipt 66 Receives Unsolicited 66 Helps Detect 66 Bone Metastases 66 Announces Dates 66 Releases Latest 66 Canaccord Genuity Reiterates Buy 66 ALVESCO ® 66 INVOS R 66 aneurysms AAA 66 MEDW 66 Breakthroughstocks.net EXPLOSIVE news 66 Inc Therapeutic Competitors 66 AMPLATZER R 66 Interesting Options Volume 66 Acquirer Company 66 Launches Groundbreaking 66 Adjuvant Chemotherapy 66 Broadens 66 Eases Pain 66 WorldHeart Announces 66 Endovascular Treatment 66 Provides Preliminary 66 Shareholders Approve Merger 66 Novel Treatments 66 Oral Suspension Oral Suspension 66 Collaborates With 66 Patent Lawsuit 66 Equity Funds Declare 66 Significantly Expands 66 Microdermabrasion Chemical Peels Collagen 66 Newly Identified 66 Obtains 66 Enrolling Patients 66 Signs Definitive Agreement 66 Novel Compounds 66 HuCAL PLATINUM R 66 Metastatic Colorectal Cancer 66 cefdinir PLEXION R 66 Commences Tender Offer 66 Patent Infringement Lawsuit 66 Latest Addition 66 Oral Solution OSMOPREP 66 Lymph Node 66 Bone Graft 66 Successfully Launches 66 Evalve MitraClip R 66 Efficacy Trial 66 Surgical Mesh 66 Achieves Prestigious 66 Tezampanel 66 Enhances User Experience 66 Optical Biopsy System 66 Receives Marketing Authorization 66 ELADUR TM 66 Demonstrates Long Term 66 R Saizen R 66 TAXUS Element Paclitaxel Eluting 66 Announces Divestiture 66 Offers Unprecedented 66 Biomarker Study 66 Study Validates 66 REVELATION ® 66 ® famotidine 66 Panasonic Develops 66 CE marked PROGENSA 66 First Patient Enrolled 66 Synthetic Peptide 66 Expands Distribution 66 Host Teleconference 66 Metastatic Melanoma 66 Settle Litigation 66 Outperforms 66 Sign Definitive Agreement 66 REPRONEX ® menotropins 66 Aneurysm Repair 66 Secondary Hyperparathyroidism 66 Report Analyzes 66 Announce Completion 66 BioElectronics Announces 66 Anti Inflammatory Drug 66 Receives Subpoena 66 Hemostatic 66 Ondansetron Injection USP 66 Hip Implants 66 Terminates Contract 66 Inhaled Corticosteroids 66 Reperfusion Injury 66 Q1 Loss Widens 66 Extends Leadership 66 Reconfirms 66 Sagent Pharmaceuticals Announces 66 Electrodes Fetal Scalp Electrodes 66 OR REFLECT THE 66 Inhalation Aerosol 66 Newest Version 66 Other OTC MNDP 66 Buy Privately Held 66 Uracyst R Test 66 submitted supplemental Biologics 66 Drug Combo 66 News Unternehmensnachrichten 66 의 을 66 Receives Conditional Approval 66 Develops Breakthrough 66 Regenerative Cell 66 Infusion Pumps 66 MRI Patient Monitoring 66 Puts Purchased 66 Completes Expansion 66 Microplate Readers 66 Cancer Cells 66 Gonal f R follitropin 66 Net Loss Narrows 66 Positive Displacement Flow Meters 66 Patent Dispute 66 Guidelines Recommend 66 Announces Formation 66 Appoints Experienced 66 David Rapperport Quest 66 Receives Notice From 66 Receives Commitment 66 Completes Acquisitions 66 AGREEMENTS SOURCE 66 siRNA Delivery 66 AP PhotoExpress Network 66 Executes Agreement 66 Software Simplifies 66 Hip Prosthesis 66 NAVIPORT ® Series 66 SIX RO ROG 66 Embolic Protection System 66 Demonstrates Sustained 66 Delivers Unprecedented 66 Assist Device 66 에 을 66 Patent Infringement Litigation 66 R MSCRAMM 66 Cloud Cover Pattern 66 Diabetic Patients 66 Tablet Formulation 66 Fast Track Status 66 Cancer Treatments 66 ATRA IV 66 Milestone Achieved 66 Augment TM 66 FDA Approves Generic 66 Resubmits 66 Researchers Identify 66 Bearish Engulfing Pattern 66 Cobalt Chromium 66 Debuts Next Generation 66 Endologix Powerlink System 66 markets HP Acthar 66 Files Voluntary 66 Deliver Powerful 66 Flamel Technologies Announces 66 R lenalidomide 66 Novartis Organon 66 Treatment Experienced 66 Ovitrelle R Serostim 66 Recalled Due 66 Treatment Shows Promise 66 Smallpox Vaccine 66 Combo Therapy 66 Terminates Agreement 66 Announce Successful Completion 66 Liberte TM 66 DuraGen Plus 66 Successfully Closes 66 Test Tubes Tubings 66 Wirtschaftsmeldungen auf ad hoc 66 BY RYAN ERNST 66 Enables Rapid 66 Medical Sorin Biomedica 66 Announce Early Termination 66 Bullish Technical Alert 66 PATHFINDER ® TRACER 66 Dural Regeneration Matrix 66 Veronate R 66 Patent Infringement Lawsuit Against 66 Genentech sanofi aventis 66 66 Consummates 66 TVS Diodes 66 Microplate Reader 66 Closes Sale 66 Terminate Merger Agreement 66 Could Save Lives 66 Endometrial Ablation 66 Expand Capabilities 66 NeutroPhase TM 66 ATS Simulus R 66 Cuts Costs 66 External Defibrillators 66 Wins Summary Judgment 66 Announce Expiration 66 Left Ventricular 66 Baerveldt ® 66 Study Shows Significant 66 OTCStockExchange.com Stock Alert 66 PRN4 66 Tumor Growth 66 Study Casts Doubt 66 Maintains Buy Rating 66 Report companiesandmarkets.com adds

Back to home page